Gilead Sciences/$GILD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Primary listing
Employees
17,600
Headquarters
Website
Gilead Sciences Metrics
BasicAdvanced
$153B
19.15
$6.42
0.35
$3.14
2.57%
Price and volume
Market cap
$153B
Beta
0.35
52-week high
$124.61
52-week low
$86.08
Average daily volume
7.4M
Dividend rate
$3.14
Financial strength
Current ratio
1.532
Quick ratio
1.175
Long term debt to equity
115.492
Total debt to equity
115.492
Dividend payout ratio (TTM)
48.31%
Interest coverage (TTM)
11.00%
Profitability
EBITDA (TTM)
13,965
Gross margin (TTM)
78.72%
Net profit margin (TTM)
27.88%
Operating margin (TTM)
38.50%
Effective tax rate (TTM)
17.96%
Revenue per employee (TTM)
$1,650,000
Management effectiveness
Return on assets (TTM)
12.38%
Return on equity (TTM)
40.71%
Valuation
Price to earnings (TTM)
19.15
Price to revenue (TTM)
5.267
Price to book
7.12
Price to tangible book (TTM)
-31.64
Price to free cash flow (TTM)
16.721
Free cash flow yield (TTM)
5.98%
Free cash flow per share (TTM)
7.356
Dividend yield (TTM)
2.55%
Forward dividend yield
2.57%
Growth
Revenue change (TTM)
2.78%
Earnings per share change (TTM)
6,514.05%
3-year revenue growth (CAGR)
2.34%
10-year revenue growth (CAGR)
-0.78%
3-year earnings per share growth (CAGR)
34.50%
10-year earnings per share growth (CAGR)
-5.14%
3-year dividend per share growth (CAGR)
2.69%
10-year dividend per share growth (CAGR)
13.83%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Bulls say / Bears say
Gilead's total Q3 2025 revenue rose 3% year-over-year to $7.77 billion, driven by a 4% increase in HIV drug sales, and its $2.43 per share earnings beat consensus estimates of $2.13, underscoring strong core performance (Reuters).
The $750 million option and license agreement with Kymera Therapeutics secures rights to innovative molecular glue degraders for breast and other solid tumors, bolstering Gilead's precision oncology pipeline with minimal near-term EPS impact (~$0.02–$0.03) (Reuters).
Gilead’s $350 million acquisition of Interius BioTherapeutics enhances its CAR-T portfolio by incorporating a scalable in-vivo delivery platform that simplifies T-cell therapy manufacturing, positioning it competitively in the fast-growing cell therapy market (Reuters).
The FDA's clinical hold on five trials of Gilead's experimental HIV drugs GS-1720 and GS-4182 due to safety concerns delays potential approvals and paused mid-to-late stage studies, causing shares to drop nearly 2% on the announcement (Reuters).
Uptake of newly approved HIV prevention injectable Yeztugo has been constrained by its exclusion from CVS Health’s pharmacy coverage over cost concerns, limiting early market penetration despite favorable clinical data (Reuters).
Core product sales declined 2% in Q3 2025 as remdesivir (Veklury) and cell therapy revenues fell, highlighting Gilead's exposure to waning COVID-19 and CAR-T segments and underscoring pressure on its diversified portfolio (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Gilead Sciences News
AllArticlesVideos
3 Cash-Rich Stocks With High Growth Potential Right Now
MarketBeat3 hours ago
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
Business Wire3 days ago
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Benzinga5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $153B as of November 06, 2025.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 19.15 as of November 06, 2025.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of November 06, 2025, the dividend rate is $3.14 and the yield is 2.57%. Gilead Sciences has a payout ratio of 48.31% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment is scheduled for December 30, 2025.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.